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Introduction 
Childhood asthma usually starts during the preschool years.
Unfortunately, it is currently not possible to test for or alter the
natural history of asthma accurately in young children,1,2 so asthma
during the preschool years is frequently underdiagnosed. About 10
asthma risk prediction indices for young children have been
developed, although only one was developed in a primary care
setting where most of these children present with respiratory
symptoms for the first time and where most are treated. Risk
stratification using prediction indices may be useful for clinical and
research purposes. For example, risk stratification supports the
tailoring of treatment strategies such that benefits and harms may
be properly weighed.3 It may therefore improve the follow-up of
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Abstract
Background: A setting-specific asthma prediction score for preschool children with wheezing and/or dyspnoea presenting in primary
healthcare is needed since existing indices are mainly based on general populations.  
Aims: To find an optimally informative yet practical set of predictors for the prediction of asthma in preschool children at high risk who
present in primary healthcare.  
Methods: A total of 771 Dutch preschool children at high risk of asthma were followed prospectively until the age of six years. Data on
asthma symptoms and environmental conditions were obtained using validated questionnaires and specific IgE was measured. At the age
of six years the presence of asthma was assessed based on asthma symptoms, medication, and bronchial hyper-responsiveness. A clinical
asthma prediction score (CAPS) was developed using bootstrapped multivariable regression methods.     
Results: In all, 438 children (56.8%) completed the study; the asthma prevalence at six years was 42.7%. Five parameters optimally
predicted asthma: age, family history of asthma or allergy, wheezing-induced sleep disturbances, wheezing in the absence of common
colds, and specific IgE. CAPS scores range from 0 to 11 points; scores <3 signified a negative predictive value of 78.4% while scores of
>7 signified a positive predictive value of 74.3%.  
Conclusions: We have developed an easy-to-use CAPS for preschool children with symptoms suggesting asthma who present in primary
healthcare. After suitable validation, the CAPS may assist in guiding shared decision-making to tailor the need for medical or non-medical
interventions. External validation of the CAPS is needed.   
© 2014 Primary Care Respiratory Society UK. All rights reserved.
LB van der Mark et al. Prim Care Respir J 2014; 23(1): 52-59 
http://dx.doi.org/10.4104/pcrj.2014.00003
Keywords preschool children, asthma, prediction, wheeze, clinical studies, sensitivity and specificity, diagnosis
* Corresponding author: Mrs LB van der Mark, Academic Medical Center of the University of Amsterdam, PO Box 22700, 1100 DE Amsterdam,
The Netherlands. Tel: +31-205664821  Fax: +31-205669186  E-mail: l.b.vandermark@amc.uva.nl
52PRIMARY CARE RESPIRATORY JOURNAL
www.thepcrj.org
http://dx.doi.org/10.4104/pcrj.2014.00003
The full version of this paper, with online appendix, 
is available online at www.thepcrj.org
09-0146 van der Mark  26/2/14  12:42  Page 1
Clinical asthma prediction score
53PRIMARY CARE RESPIRATORY JOURNAL
www.thepcrj.org
children at risk by decreasing the disease burden and improving
management, resulting in fewer respiratory symptoms,
exacerbations, and emergency medical visits.4,5 
Prediction indices are valuable because the information itself
may contribute to patients’ quality of life.6 Patients’ emotional
response to medical testing is a natural effect. The information
involved in a high predicted probability of a young child having
asthma at six years of age may enable them (or their
parent/guardians) to make sense of the symptoms or to adjust their
lifestyle and living conditions in light of the results, while a low
predicted probability may alleviate their concerns.6,7
In addition, various research groups are investigating the
underlying pathogenic mechanisms and preventive strategies for
asthma,8 and as soon as effective therapy that is either costly and/or
has adverse effects emerges, risk stratification will be useful.3
Existing predictive indices have an uncertain value for the primary
healthcare setting because the majority of the cohort studies were
based on parental questionnaires in a general population,9-13 so they
are of modest clinical value for preschool children.14 For example, the
most well-known indices – the loose and stringent Asthma Predictive
Indices (API) – were developed in a general population and are based
on questionnaires.9 API predicts persistent wheezing in children who
ever wheezed and does not predict asthma in children with recurrent
wheeze presenting to a physician.15
In 2004 we started a prospective cohort of young children at
high risk of developing asthma. The objective was to construct a
clinical index for predicting asthma in preschool children at risk of
asthma presenting in primary care. Here we describe the
development and performance of a novel clinical asthma prediction
score (CAPS). 
Methods 
Design and subjects  
The subjects were children aged one to five years in the Netherlands
who were participating in the ARCADE (AiRway Complaints and
Asthma Development) prospective cohort study.4 They had
presented at one of the pertinent 14 primary care clinics in the
previous 12 months with complaints of recurrent coughing (>2
visits), wheezing (>1 visit), and/or shortness of breath (>1 visit). The
study was approved by the Netherlands Central Committee on
Research Involving Human Subjects (CCMO/P04.0098C) and the
details of the study have been published elsewhere.4 Written
informed consent was obtained from the parents before all
measurements.  
Data collection 
Questionnaires      
For this study we derived demographic data and data with respect to
the child’s clinical history from questionnaires obtained by the Core
Questionnaire of the International Study of Asthma and Allergy in
Children (ISAAC), which was administered at baseline and at the age
of six years.  
Allergy test       
Total immunoglobulin E (IgE) and specific IgE directed against cat,
dog, and house dust mite were determined by radioallergosorbent
test (RAST) in all the children at baseline. IgE positivity to cat, dog, and
house dust mite was defined as >0.35kU/L.4
Spirometry and bronchial hyper-responsiveness        
At six years of age, spirometry and bronchial hyper-responsiveness
(BHR) assessments were obtained in children with wheezing,
shortness of breath, recurrent coughing, or use of asthma medication
(β2-agonists, inhaled corticosteroids) during the previous 12 months.
BHR to increasing doses of methacholine was measured according to
Cockcroft et al.(online supplement reference 3). 
Outcome: asthma diagnosis at age six     
The diagnosis of asthma at six years of age was defined as: having
persistent symptoms of asthma and/or using asthma medication in
the last year in combination with BHR (defined as the methacholine
dose (<8.0mg/ml) causing a 20% reduction in forced expiratory
volume in one second (PC20-FEV1)) or reversibility (>10% increase in
FEV1 after short-acting β2-agonists).4 Persistent symptoms were
defined as self-reported complaints during the previous 12 months of
wheezing and/or shortness of breath and/or recurrent coughing. 
Children who had not experienced asthma-related symptoms in
the previous year or who had not used asthma medication in the
previous year were not invited for lung function measurement. They
were considered as not having asthma.
Probability of asthma at the age of six 
Depending on the direction and magnitude of the selected
predictors as measured by regression coefficients, we developed the
Clinical Asthma Prediction Score (CAPS) as a points system which is
easy to use, without requiring a computer or calculator.16 To use the
CAPS in clinical practice, thresholds are needed to either rule in or
rule out asthma at the age of six years. Therefore we set two
thresholds – a lower limit at 30% below which we assumed that
many physicians may well choose a ‘wait and see’ policy, and an
upper limit at 60% above which it was assumed that physicians may
pursue a more active management such as a trial of asthma
treatment. These thresholds imply that children with a predicted risk
of asthma risk between 30% and 60% will be assigned to the area
of clinical indecision in which a ‘watchful waiting’ policy may be
defensible. 
Statistical analysis 
Details of the statistical analysis are described in Appendix 1,
available online at www.thepcrj.org. Briefly, we analysed whether
dropout was selective and missing predictor data were imputed
using multiple imputation.17 Twelve candidate predictors of all
available data were preselected based on clinical expert opinion
after removing five due to collinearity (Table 1). Bootstrapped
(1000x) backward selection was used to select the final important
predictors whose regression coefficients were shrunk to facilitate
better performance when the model is applied to other data or
future patients.18 The predictive performance of the prediction index
was assessed by its calibration and discrimination abilities. 
Furthermore, the additional value of specific IgE was calculated
by the additional area under the ROC curve (AUCdiff) and the net
reclassification improvement (NRI).19 All statistical analyses were
carried out in Stata/SE Version 10.1 (Stata Corp, College Station, TX,
USA).
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Candidate variables Asthma diagnosis at age 6 years
No (n=251) Yes (n=187) All (n=438)
Mean (SD) age at baseline, years 2.71 (1.23) 3.39 (1.26) 3.00 (1.29)
1–2 98 (39) 34 (18) 132 (30)
2–3 63 (25) 35 (19) 98 (22)
3–4 37 (15) 47 (25) 84 (19)
4–5 36 (14) 54 (29) 90 (21)
>5 17 (7) 17 (9) 34 (8)
Perinatal factors
Female 110 (44) 79 (42) 189 (43)
Breastfeeding >3 months (2 missing) 107 (43) 86 (46) 193 (44)
Reported symptoms in past year
Nightly persistent mucous cough or phlegm apart from a cold1* (5 missing): yes 78 (31) 85 (46) 163 (38)
Dry cough at night, apart from a cold2* (6 missing): yes 112 (45) 109 (59) 221 (51)
Coughing episode > 1 month3* (4 missing): yes 31 (12) 41 (22) 72 (17)
Wheezing4 :yes 133 (53) 126 (67) 259 (59)
Frequency of wheezing attacks5* (1 missing)
None 117 (47) 61 (33) 178 (41)
1–3 times 103 (41) 78 (42) 181 (41)
>4 times 30 (12) 48 (25) 78 (18)
Wheezing-induced sleep disturbances6 (3 missing): yes 61 (25) 82 (44) 143 (33)
Wheezing during or in absence of cold7 (3 missing): 
No 121 (49) 62 (33) 183 (42)
Yes, only with cold 100 (40) 80 (43) 180 (41)
Yes, with and without cold 28 (11) 44 (24) 72 (17)
Itch/eczema8 (3 missing) 78 (31) 74 (40) 152 (35)
Allergy child
Allergy (ever)9* (2 missing) (doctor’s diagnosis) 31 (12) 45 (24) 76 (17)
Allergy child – IgE dichotomous
Specific IgE against cats, dogs, and/or house dust mite10 (96 missing) 23 (12) 65 (41) 88 (26)
Environmental factors
Parental smoking in child's presence11 (3 missing) 33 (13) 30 (16) 63 (14)
Child has older sibling 132 (53) 96 (51) 228 (52)
Family history
Asthma, parents, and/or siblings12 (3 missing) 76 (31) 80 (43) 156 (36)
Allergy, parents, and/or siblings13 (3 missing) 98 (28) 93 (33) 191 (31)
*Variables not used in bootstrapped backward selection. Numbers are n (percentages in parentheses) unless stated otherwise. IgE=immunoglobulin E.
1. In the last 12 months, has your child usually seemed congested in the chest or has she/he coughed up phlegm (mucus) during the night when she/he did not have a cold? 
2. In the last 12 months, has your child had a dry cough at night, apart from a cough associated with a cold or chest infection? 
3. In the last 12 months, has your child coughed for more than 5 days a week over a period longer than 1 month?
4. Has your child had attacks of wheezing in the last 12 months?
5. How many attacks of wheezing has your child had in the last 12 months?
6. In the last 12 months, has your child’s sleep been disturbed due to wheezing?
7. Combination of questions (1) In the last 12 months, has your child’s chest sounded wheezy associated with a cold? and (2) In the last 12 months, has your child’s chest 
sounded wheezy not associated with a cold?
8. Has your child had an itchy rash which was coming and going for at least six months in the last 12 months?
9. Has a doctor ever diagnosed one or more allergies? 
10.Specific IgE positivity to house dust mite, cat, and/or dog dander was defined as >0.35kU/L.
11.Does at least one of the parents smoke in the parental house?
12.Does at least one of the parents and/or siblings have asthma? Variable was collected by questionnaire. In the analyses it was combined with ‘Allergy, parents, and/or siblings’
13.Does at least one of the parents and/or siblings have allergies to pets, pollen, and/or house dust mites? Variable was collected by questionnaire. In the analyses it was combined
with ‘Allergy, parents, and/or siblings’.  
Table 1. Candidate predictors of asthma diagnosed at 6 years of age in preschool children
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Results
Of the 771 children, 438 (56.8%) had complete information at
baseline and an asthma diagnosis at the endpoint (Figure 1). Of
these, 187 (42.7%) had asthma at the age of six. Table 1 shows the
univariable frequencies of the preselected candidate predictors. The
mean (SD) age at baseline was 3.00 (1.29) years and 189 (43.1%)
were female. In 156 children (35.6%), asthma was present in either
the parents or siblings. Missingness analyses showed no strong
indications for selective drop out (Appendix 1 available online at
www.pcrj.org).
Multivariable analysis      
Five predictors were included (Table 2): age, family history of asthma
or allergy, wheezing-induced sleep disturbances in the previous 12
months, wheezing in the absence of a cold in the previous 12
months, and specific IgE test. The discrimination of the model
expressed as area under the ROC curve was 0.73 (SE=0.024).
Calibration was satisfactory (Table 2). 
IgE and no IgE in the model       
The model performance was calculated for the model including
age, family history, wheezing-induced sleep disturbances, and
wheezing in the absence of a cold but excluding IgE. The
discrimination of the model expressed as area under the ROC
curve was 0.71 (SE=0.024). Calibration was good (Table 2).
Adding specific IgE to the model increased the AUC by 2.8
percentage points (AUCdiff= 0.028, 95% CI 0.0047 to 0.051,
SE=0.012). Net reclassification analysis showed that 11.23%
(p=0.09) of the children were correctly reclassified when IgE was
added to the model based on history items only (Table 3).19
Probability of asthma at the age of six using CAPS
A points system ranging from 0 to 11 was developed. Thresholds to
Clinical asthma prediction score
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Figure 1.  Flow diagram
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accept or reject the presence or development of asthma were set at
30% and 60%, respectively (Table 4).16 The positive predictive values
(PPVs) of the CAPS (>7=probability of asthma of >60%) were 74.3%
(CAPS=7) and 100% (CAPS=11) and the negative predictive values
(NPVs) of the CAPS (<3=probability of asthma of ≤30%) were 78.4%
(CAPS=2) and 88.2% (CAPS=0) (see online supplement). Figure 2
shows asthma risks as a function of CAPS scores. 
Discussion  
Main findings    
The clinical asthma prediction score (CAPS) we developed in a
prospective cohort study facilitates the risk stratification of preschool
children who attend primary healthcare with wheezing, dyspnoea,
or recurrent coughing. The predictive ability of the CAPS may assist
physicians to distinguish between a relatively low risk (14%) and a
very high risk (90%) of developing asthma. The CAPS uses easily
accessible information on age, family history of asthma or allergy,
wheezing-induced sleep disturbances, and wheezing in the absence
Predictors OR* p Value 95% CI
Age (year): linear 1.47 0.000 1.24 to 1.75
Specific IgE positive: yes or no 2.45 0.003 1.38 to 4.33
Asthma or allergy, parents and/or siblings 1.54 0.060 0.98 to 2.41
Wheezing-induced sleep disturbances 2.08 0.002 1.31 to 3.29
Wheezing, in absence of cold 2.22 0.008 1.23 to 3.99
Discrimination, calibration, reclassification AUC (SE) HL (p) NRI (SE)**
Extended model (including all predictors) 0.73 (0.024) 4.51 (>0.75)
Simple model (excluding IgE) 0.71 (0.024) 7.15 (>0.61)
Comparisons between the models AUCdiff 0.028 (0.012)# 11.23 (0.05)##
*OR = odds ratio before fixed shrinkage (shrinkage factor k=0.949), NRI=net reclassification improvement. **Thresholds are 30% and 60%. # p=0.019; ##p=0.09.
Table 2. Predictors for asthma at age of six years and prediction model performance measures
Asthma present Model including IgE
<30% 30-60% >60% Total
Model <30% 25 (13.4) 11 (5.9) 0 (0) 36 (19.3)
excluding 30-60% 7 (3.7) 61 (32.6) 21 (11.2) 89 (47.6)
IgE >60% 0 (0) 13 (7.0) 49 (26.2) 62 (33.2)
Total 32 (17.1) 85 (45.5) 70 (37.4) 187 (100)
Asthma absent Model including IgE
<30% 30-60% >60% Total
Model <30% 82 (32.7) 17 (6.8) 0 (0) 99 (39.4)
excluding 30-60% 27 (10.8) 91 (36.3) 8 (3.2) 126 (50.2)
IgE >60% 0 (0) 9 (3.6) 17 (6.8) 26 (10.4)
Total 109 (43.4) 117 (46.6) 25 (10.0) 251 (100)
NRI is 11.23% (CI –0.018 to 0.243; p=0.09), which means that 11.23%
are correctly reclassified in the extended model.
Table 3. Reclassification tables for model with or
without IgE in children with and without asthma 
Risk factor Categories CAPS CAPS Mean probability (%) 95% CI
Age 1-2 0
2-3 1 0 13.5 8.8 to 20.3
3-4 2 1 19.0 13.3 to 26.3
4-5 3 2 24.4 17.0 to 33.8
>5 4 3 32.3 22.7 to 43.6
sIgE Negative 0 4 41.1 30.3 to 52.9
Positive 2 5 50.4 37.5 to 63.2
Asthma or allergy, parents and/or siblings Negative 0 6 59.1 45.5 to 71.4
Positive 1 7 67.6 54.1 to 78.7
Wheezing-induced sleep disturbances No 0 8 76.7 64.1 to 85.9
Yes 2 9 82.2 69.9 to 90.2
Wheezing in absence of cold No 0 10 87.1 76.9 to 93.2
Yes 2 11 89.7 80.4 to 94.9
Score (CAPS) 0-11
95% CI=95% confidence interval.
Table 4. Risk estimates associated with Clinical Asthma Prediction Score (CAPS) points
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of a cold, and an additional blood sample to obtain specific IgE. 
The use of the CAPS may enable physicians to reduce the
number of children unnecessarily labelled with asthma (low CAPS).
For this group, the prior probability went from 42.7% to 21.6%; this
helps to reduce unnecessary testing, treatment, and uncertainty. On
the other hand, CAPS may allow physicians to identify preschool
children who may need proper asthma management (high CAPS).
For this group, the prior probability went from 42.7% to 74.3%; a
high CAPS may therefore reduce the burden of asthma in these
children through better symptom control and fewer exacerbations
and hospital admissions. In both situations there will be a reduction
in costs. Children with an intermediate CAPS (3>7) retain a
probability similar to the probability before applying the CAPS. In this
group a watchful waiting policy seems justified, in line with the
British guideline,20 which subsequently suggests a watchful waiting
approach with review in the majority of cases with intermediate risk
predictions. 
Strengths and limitations of this study     
Our study has the following strengths. First, we selected children
from a relevant population – namely, those children in whom an
attending primary care physician had considered asthma. Second, all
predictors collected are easily accessible in primary care. Third, we
used a stringent definition of asthma to ensure a reliable reference
standard diagnosis for research purposes. Fourth, we followed the
relevant STARD checklist criteria – a strict protocol with well-defined
inclusion and exclusion criteria for the setting and population and a
generally accepted reference standard.21 Fifth, shrinkage of the
magnitude of the regression coefficients was used to counteract
over-optimism of our model, thus enhancing its validity outside our
data set.17,18 Sixth, we used NRI to measure the additional value of
specific IgE to the model. NRI is a marker to express the model
performance and to compare models, focusing on the correct
reclassification of patients with and without asthma; it appears to be
a clinically more sensible approach than the differences between
AUCs.  
We see the following limitations to our work. First, our study is
a model development study without external validation. We did,
however, use bootstrapped variable selection and shrinkage of
regression coefficients to temper an over-optimistic performance of
CAPS in external populations. Second, we have a high dropout rate.
Missingness analyses showed that dropout was higher in children of
parents who smoked (OR=1.88) and those with persistent (>1
month) coughing (OR=1.62). Parental smoking may be explained as
a psychological cause for dropout; parents who smoke may feel
guilty or embarrassed that smoking might have a negative influence
on their child’s physical condition. We assumed that persistent
coughing as a cause of dropout was a coincidental finding. The high
dropout rate may also be explained by the fact that, due to an
extension of follow-up, participants had to explicitly renew their
informed consent. Third, although some combinations of predictor
values yield low (<30%) or high (>60%) asthma probabilities, almost
58% of the children in our study population had a predicted
probability between 30% and 60%, close to the overall prevalence
of 42%. For such children, CAPS results are not likely to change
clinical management. Finally, the choice of different thresholds may
lead to different results. As far as we are aware, there is no evidence-
based advice on thresholds for this type of decision-making in the
asthma literature. We decided to use thresholds as a clinically
intuitive alternative to more formal methods of reclassification and
as an attractive alternative for classical methods of predictive
performance such as the area under the ROC curve.22 We chose a
lower limit of 30% to rule out asthma and an upper limit of 60% to
rule it in, which implies an area of indecision between the
probabilities of 30% and 60%. We think that these limits – or limits
close to these – may be relevant in daily primary care practice.23
However, evidence-based thresholds would require formal benefit-
harm or cost-utility analyses that incorporate treatment effects,
potential harms (and costs), and children’s (and their parents’)
valuation of all different health outcomes. Although utility
measurement in children is not simple, instruments to measure
quality of life in children do exist.24,25 
Interpretation of findings in relation to previously
published work 
The API represents innovative research and is the most investigated
index. This index was developed in the Tucson general population
cohort9 and has also been tested in other populations (e.g. in the
Leicester Respiratory Cohort, n=1,954). Unfortunately, one of the
predictors – a blood sample for eosinophilia at one year of age – was
omitted from the Leicester cohort.26
Several predictive indices for preschool children have been
published in the past years.9-13,27-31 However, the populations in which
these indices were developed are atypical of primary care, which
may limit their application in the relevant spectrum of high-risk
children in primary care. Nevertheless, most indices were
prospectively developed and a number of selected predictors
correspond reasonably well with ours: family history of atopy or
asthma, persistent airway complaints (mainly wheezing), eczema,
Clinical asthma prediction score
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Figure 2.  Probability of having asthma at age 6 years,
including 95% confidence internvals, associated with
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allergic rhinitis, and allergic blood testing. An important difference
between the CAPS and other indices is the endpoint: only Eysink et
al. developed their index with a comparable outcome – namely, a
strict definition of the diagnosis of asthma.29 The major difference
between the CAPS and the prediction index of Eysink et al. is that
we used clinically more relevant inclusion criteria, which is reflected
in the higher overall prevalence of asthma. The other published
indices used varying ‘asthma’ definitions, mainly persistent wheezing
at a specific age (varying from six to 13 years),9-13,28,31 or asthma
defined by asthma symptoms or a physicians’ diagnosis of asthma at
age six to 10 years.9,27,30,31 Using weak and varying definitions may
cause variation in prevalences and prediction indices, hampering
generalization of findings.23
Most research groups used different populations to develop their
indices and did not focus on the target population (i.e. preschool
children presenting with respiratory complaints to their primary care
physician). Eysink et al. included children aged one to four years
visiting their primary care physician for persistent coughing of at
least five days, and followed them to develop a predictive index for
persistent asthma.29 Vial Dupuy et al. retrospectively selected
wheezing infants from the medical files of an outpatient department
of a paediatric pulmonology and allergy centre. The present study
resembles the earlier Dutch study in the primary care setting except
that the previous study was retrospective and the children were
younger.31 Frank et al. selected their patients by postal survey on
parent-reported wheeze, although this matched the clinicians’
findings in fewer than 50% of cases.11,32 In the seven remaining
studies, the participants were selected from general population birth
cohorts,9,10,12,13,27,28,30 which makes these indices of doubtful
applicability to most clinical settings unless major adaptations are
made.
The predictive abilities of existing indices are, in general, not
high. For example, Castro-Rodriguez et al. claim that the API is a
‘very useful tool’ to predict the long-term outcome of preschool
wheeze ‘in every healthcare setting worldwide’. However, it was
calculated that the performance of the API in more high-risk
populations would be poorer.15 A negative API result in the Tucson
cohort (‘asthma’ prevalence at age six of 22.2%) yielded a 10%
probability of asthma (NPV=0.90). Overall, earlier predictive indices
also had relatively high NPVs but disappointing PPVs, which makes
them more useful to rule out asthma than to rule it in.26 
Implications for future research, policy and practice 
The implementation of a simple risk score in daily care is attractive to
both physicians and parents. It allows physicians to provide tailored
medical care and follow-up in children at high risk of developing
asthma, and to apply a wait-and-see policy in those with a low or
intermediate risk of asthma. The increased likelihood of predicting
which children will develop asthma will help physicians to explain
treatment and prognosis to parents, reducing uncertainties and
improving adherence in their children. 
Our study was a model development study, extended with
internal validation using bootstrapped variable selection and
shrinkage of regression coefficients, with the aim of developing a
multivariable prediction model. Before the model can be confidently
applied in daily clinical practice, external validation is needed.18 Also,
further research should focus on new markers or tests to decrease
the number of patients remaining inside the area of indecision (i.e.
to increase discrimination).
Risk stratification serves three distinct functions in controlled
trials: (1) assembling the appropriate spectrum of patients and
allowing more efficient subgroup analysis14 and better assessment of
baseline comparability; (2) it may also distinguish persistent and
transient complaints early on and therefore increase the accuracy of
the RCT results;3 and (3) the CAPS may be used to re-analyse early
intervention trials to assess treatment response variability as a
function of the CAPS score.3 Such trials should, of course, allow the
calculation of a CAPS score.
Conclusions   
We have developed an easy-to-use CAPS for preschool children at
high risk of asthma in a primary healthcare setting. After suitable
validation, the CAPS may assist in guiding shared decision-making to
tailor the need for medical or non-medical interventions. 
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Appendix 1.  Supplementary material
Methods
Design 
The subjects were one- to five-year-old children in an urban
agglomeration in the western part of the Netherlands who were
participating in the ARCADE (AiRway Complaints and Asthma
Development) prospective cohort study,1 and had presented at one
of the pertinent 14 primary care clinics in the previous 12 months
with complaints of recurrent coughing (>2 visits), wheezing(>1 visit),
and/or shortness of breath (>1 visit).
The study was approved by the Netherlands Central Committee
on Research Involving Human Subjects (CCMO/P04.0098C). 
Subjects
Eligible for participation were children aged one to five years who
visited their primary care physician (in the Netherlands always a
primary care physician) with the respiratory complaints of wheezing
and/or dyspnoea in the previous 12 months or following 6 months
after the start of ARCADE. Children who visited their primary care
physician at least twice with the symptom of coughing were also
eligible. Exclusion criteria were a confirmed diagnosis of asthma at
inclusion (based on spirometry and challenge test), known
temporary stay in the region, or parents unable to read or
understand Dutch/English. The primary care physician sent postal
information about the study to the parents (or caregiver, from now
on called ´parent´) of eligible children, including a reply card, which
they could return if they considered participation. After returning the
card, further detailed written information and an informed consent
form was sent. 
Data collection 
Questionnaires
At baseline (T0) and at age 6 years (Tend) the parents received a
questionnaire on (changes in) housing conditions, family history of
allergy, asthma and eczema, presence of pets, breastfeeding, and
asthma-related symptoms. Also, information about wheezing,
rhinitis, eczema, cough, and phlegm was obtained by the Core
Questionnaire of the International Study of Asthma and Allergy in
Children (ISAAC).2
Allergy test
Total immunoglobulin E and specific IgE directed against cat (C), dog
(D), and house dust mite (HDM) were determined by
radioallergosorbent test (RAST) in all the children at baseline.3 IgE
positivity to house dust mite, cat and/or dog dander was defined as
>0.35kU/L.1 The blood samples were investigated by independent
chemical analysts.
Spirometry and bronchial hyper-responsiveness 
At six years of age spirometry and bronchial hyper-responsiveness
(BHR) assessments (using Pulmoassist 2 spirometer; Jaeger,
Würzburg, Germany) was obtained in children with symptoms
(wheezing, shortness of breath or recurrent coughing) or use of
asthma medication (β2-agonists, inhaled corticosteroids (ICS)) during
the prior 12 months. BHR to increasing doses of methacholine was
measured according to the modified method of Cockcroft et al.
(using DeVilbiss 646 nebuliser; DeVilbiss, Somerset, MA, USA, with
an output of 0.13mL/min).4 Tests were conducted by independent
lung function assistants. The parents of children using asthma
medication were asked to withhold all bronchodilators for 48 hours
prior to the test. In the case of shortness of breath, children received
ongoing short-acting β2-agonists up to 8 hours before the test.1
Candidate variables OR p Value 95% CI
Inclusion criteria
Coughing 0.777 0.268 0.498 to 1.214
Wheezing 0.721 0.054 0.518 to 1.005
Shortness of breath 1.056 0.775 0.728 to 1.531
Characteristics
Age 0.62 <0.001* 0.53 to 0.73
Female 1.06 0.747 0.74 to 1.51
Breastfeeding >3 months 1.02 0.926 0.71 to 1.46
Parental smoking 1.89 0.001** 1.32 to 2.71
Child has sibling(s) 1.01 0.977 0.7 to 1.45
Asthma, parents, and/or sibling(s) 0.915 0.660 0.62 to 1.36
Allergy, parents, and/or sibling(s) 0.7 0.065 0.48 to 1.02
Reported symptoms in past year
Nightly persistent mucous cough 1.0 0.995 0.67 to 1.48
or phlegm apart from a cold
Dry cough at night, apart from 0.99 0.950 0.67 to 1.46
a cold
Coughing episode >1 month 1.62 0.038** 1.03 to 2.55
Wheezing 0.47 0.048* 0.22 to 0.99
Frequency of wheezing attacks 0.89 0.506 0.63 to 1.26
Wheezing-induced sleep 1.17 0.531 0.72 to 1.91
disturbances
Wheezing, in absence of cold 1.39 0.211 0.83 to 2.32
Wheezing, in absence of exercise 0.79 0.300 0.50 to 1.24
Shortness of breath-induced 1.15 0.502 0.76 to 1.74
sleep disturbances
Complaints of rhinitis 0.94 0.748 0.64 to 1.38
Itch/eczema 0.95 0.771 0.66 to 1.36
Allergy child 
Specific IgE against cats, dogs, 1.036 0.931     0.466 to 2.301
and/or house dust mite
Other
Drug use for airway complaints 1.0 0.993 0.65 to 1.54
Referral to hospital 1.06 0.829 0.63 to 1.80
Multivariable logistic regression analyses were performed on 730 children for 
inclusion criteria, for all other variables on 597 children, accept for specific IgE 
(n=338).
* Lower dropout rate, has no influence, because variables are selected by BBS in 
final model.5
** Higher dropout rate. 
Table A1. Dropout analyses
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Outcome: asthma status at age six
The diagnosis of asthma (masked for predictor values) at six years of
age was defined as having persistent symptoms of asthma and/or
using asthma medication in the last year in combination with BHR
(defined as the methacholine dose (<8.0mg/ml) causing a 20%
reduction in FEV1 (PC20-FEV1)) or reversibility (>10% increase in FEV1
after short-acting β2-agonists).1 Persistent symptoms were defined
as self-reported complaints during the previous 12 months of
wheezing and/or shortness of breath and/or recurrent coughing.
Children who had not experienced the asthma-related
symptoms in the previous year or who had not used asthma
medication were not invited for lung function measurement. They
were considered as not having asthma.
Probability of asthma at the age of six
Depending on the direction and power of the selected predictors
measured by regression coefficients, we developed a clinical asthma
prediction score (CAPS) as a points system that is easy to use and
does not require a computer or calculator.5 To use the CAPS in
clinical practice, thresholds are needed to either rule in or rule out
asthma at the age of six years. We set two thresholds – a lower limit
at 30% below which we assumed that many physicians may well
choose a “wait and see” policy and an upper limit at 60%, assuming
that physicians may pursue more active management such as a trial
of asthma treatment. These thresholds imply that children with a
predicted asthma risk of between 30% and 60% were assigned to
the area of clinical indecision in which a “watchful waiting” policy
may be defensible.
Statistical analysis
Analyses of dropouts
Multivariable logistic regression was used to analyse selective
dropout (see Table A1). First we analysed the dropout on inclusion
criteria (n=730), coughing, wheezing or shortness of breath.6
Second, we analysed for selective dropout using the other candidate
variables (n=597). 
Handling of missing data
Multiple imputations using all predicting covariates by iterative
chained equations (ICE) to replace missing values were used. Ten
imputed datasets were generated.7
Development of the model
Candidate predictors were selected based on clinical expert opinion.
In the case of highly correlated candidate predictors (if Spearman
>0.7), only one was analysed. Further, predictors were selected using
bootstrapped backward selection (BBS method) with a significance
level α of 0.157 (Akaike information criterion; AIC), by fractional
polynomial multivariable modelling according to Royston and
Sauerbrei.8 In each imputed dataset, backward variable selection was
used in 1,000 bootstrapped samples; if the bootstrap inclusion
fraction (BIF) of a covariate was more than 667/1,000 in each
imputed dataset, it was selected as a predictor. After selecting the
predictors, the coefficients of the predictors were multiplied by a
fixed heuristic shrinkage factor.9
Performance of asthma prediction model
The predictive performance of the asthma prediction model was
assessed by calibration and discrimination. Calibration (Hosmer-
Risk factor Categories Reference βi βi(Wij-WiREF) βi(Wij-WiREF)/B Score
value (Wij) Pointsij (CAPS)
Age 0.367
1-2 1.5=WiREF 0 0 0
2-3 2.5 0.367 1 1
3-4 3.5 0.734 2 2
4-5 4.5 1.101 3 3
>5 5.5 1.468 4 4
Specific IgE 0.849
Negative 0=WiREF 0 0 0
Positive 1 0.849 2.313 2
Asthma or allergy, parents and/or siblings 0.409
No 0=WiREF 0 0 0
Yes 1 0.409 1.114 1
Wheezing-induced sleep disturbances 0.694
No 0=WiREF 0 0 0
Yes 1 0.694 1.891 2
Wheezing in absence of cold 0.756
No 0=WiREF 0 0
Yes 1 0.756 2.059 2
Max score (CAPS) 11
βi = coefficient after shrinkage. † Method according Sullivan et al.4
Table A2.  Calculations for CAPS†.  Model with the shrunk coefficients.  B=0.367 (increase in risk associated with a 1-
year increase in age: B=1(0.367)=0.367)
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Lemeshow test) describes the accuracy of the measurements
between the observed probabilities and the predicted probabilities in
independent datasets. Discrimination represents the model’s ability
to discriminate between patients with and without asthma during
our study. The most familiar measurement for discrimination is the
area under the receiver operating characteristic (ROC) curve or
concordance (c) statistic: a value of 0.5 represents chance and a
value of 1 represents perfect discrimination. 
Reclassification/NRI
The additional value of the most invasive predictor – namely, blood
testing on specific IgE – was calculated using the area under the ROC
curve (AUCdiff) and the NRI, an instrument that focuses on the
reclassification of patients with and without asthma. The thresholds
were <30% for a small probability of asthma at the age of six years
and >60% for a very high probability of having asthma in later life.
In the light of the upward movement for events and the downward
movement for non-events, an index could be calculated.10 In
addition, the results (including SE and 95% CI) were bootstrapped
1000 times in order to test the AUCdiff.11
Probability of asthma at age six by clinical asthma
prediction score (CAPS) 
To make complex statistical models useful to practitioners, Sullivan et
al. developed a points system that is easy to use and does not require
a computer or calculator5 (see Table A2). After organising risk factors
into categories and determining reference values, referent risk factor
profiles (WiREF, i=1,…,4) were selected for each risk factor. A
constant (B) was defined, reflecting the increase in risk associated
with a 1-year increase in age (B=1*(0.333)=0.333). Points associated
with each of the categories of the risk factors were computed by:
Pointsij=βi(Wij-WiREF)/B. Points were rounded to the nearest integer.5
Further, the estimates of the risk associated with each point total
was determined by calculating the linear predictor and probability
using the multiple logistic regression equation (Figure A1).
Furthermore, the positive predictive and negative predictive values of
CAPS (>7 and <3=probability of asthma of >60% and ≤30%,
respectively) were calculated (see Table A3).
To estimate the risk of developing asthma based on the statistical
model, the simplified CAPS could be used in daily practice. 
All statistics were carried out in Stata/SE Version 10.1 (Stata
Corp, College Station, TX, USA).
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PPV 55/74=0.743 (95% CI 63.3 to 82.9)
NPV 87/111=0.784 (95% CI 96.8 to 85.0)
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